BioLineRx Ltd. - American Depositary Shares (BLRX)
BLRX moved a median of -0.82% 30 minutes after news, and -0.20% by the close. How BLRX actually reacts to news — the realized, point-in-time move the market made, measured across 148 labeled events over the last three years with zero look-ahead.
BLRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.55% | 26% | 140 |
| 30-min | -0.82% | 40% | 147 |
| 60-min | -0.73% | 38% | 147 |
| to close | -0.20% | 47% | 148 |
| Middle 50% of BLRX reactions | -3.52% to +0.85% |
|---|---|
| Median reaction (30-min) | -0.82% |
| Measured reactions | 148 |
Half of all BioLineRx Ltd. - American Depositary Shares news events land between -3.52% and +0.85% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BLRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 19 | -2.80% | 26% | -2.14% |
| Rating reiterations | 19 | -0.64% | 42% | -0.58% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how BLRX ranks against every other measured name →
That’s how BLRX usually reacts — get an email when it moves on news →Email me when BLRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BLRX's baseline. Nothing else.
Recent BLRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day | Press release | PR Newswire | +0.00% | -4.33% | |
| Form EFFECT BioLineRx Ltd. | SEC filing · Form EFFECT | SEC EDGAR | — | -2.11% | |
| Form F-1 BioLineRx Ltd. | SEC filing · Form F-1 | SEC EDGAR | -2.40% | -2.80% | |
| Form 6-K BioLineRx Ltd. For: Sep 24 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +4.42% | |
| BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) | Press release | PR Newswire | +1.98% | +1.56% | |
| Form 6-K BioLineRx Ltd. For: Sep 10 | SEC filing · Form 6-K | SEC EDGAR | +1.98% | +1.56% | |
| Form D BioLineRx Ltd. | SEC filing · Form D | SEC EDGAR | +1.98% | +1.56% | |
| BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | -10.35% | -3.45% | |
| Form 6-K BioLineRx Ltd. For: Aug 31 | SEC filing · Form 6-K | SEC EDGAR | +3.77% | +5.28% | |
| Form 6-K BioLineRx Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -10.35% | -3.45% | |
| BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement | Press release | PR Newswire | +3.13% | +1.56% | |
| Form 6-K BioLineRx Ltd. For: Aug 28 | SEC filing · Form 6-K | SEC EDGAR | +3.13% | +1.56% | |
| BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 | Press release | PR Newswire | — | -2.40% | |
| Form 6-K BioLineRx Ltd. For: Aug 18 | SEC filing · Form 6-K | SEC EDGAR | — | +1.74% | |
| BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 | Press release | PR Newswire | -0.69% | -2.75% | |
| BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model | Press release | PR Newswire | +3.58% | +7.88% | |
| Form 6-K BioLineRx Ltd. For: Jul 08 | SEC filing · Form 6-K | SEC EDGAR | +3.58% | +7.88% | |
| BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | -5.46% | +2.12% | |
| Form 6-K BioLineRx Ltd. For: May 27 | SEC filing · Form 6-K | SEC EDGAR | -5.46% | +2.12% | |
| BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting | Press release | PR Newswire | -1.37% | +4.79% | |
| Form 6-K BioLineRx Ltd. For: May 22 | SEC filing · Form 6-K | SEC EDGAR | -1.37% | +4.79% | |
| BioLineRx to Report First Quarter 2026 Results on May 27, 2026 | Press release | PR Newswire | — | +4.96% | |
| BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts | Press release | PR Newswire | -0.37% | -3.31% | |
| Form 6-K BioLineRx Ltd. For: May 19 | SEC filing · Form 6-K | SEC EDGAR | -0.37% | -3.31% | |
| BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | Press release | PR Newswire | -0.42% | +9.58% | |
| Form 6-K BioLineRx Ltd. For: Apr 28 | SEC filing · Form 6-K | SEC EDGAR | -0.42% | +9.58% | |
| Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma | Press release | Business Wire | +0.00% | +0.00% | |
| Form 20-F/A BioLineRx Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | -6.25% | |
| BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | Press release | PR Newswire | -4.79% | -10.73% | |
| Form 6-K BioLineRx Ltd. For: Mar 26 | SEC filing · Form 6-K | SEC EDGAR | -4.79% | -10.73% | |
| BioLineRx Reports 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.00% | -10.43% | |
| Form 20-F BioLineRx Ltd. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | -10.43% | |
| Form 6-K BioLineRx Ltd. For: Mar 23 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -10.43% | |
| BioLineRx to Report 2025 Annual Results on March 23, 2026 | Press release | PR Newswire | +0.00% | +2.73% | |
| Form 6-K BioLineRx Ltd. For: Feb 23 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +1.40% | |
| Form S-8 BioLineRx Ltd. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -0.65% | |
| BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | -1.75% | +2.04% | |
| Form 6-K BioLineRx Ltd. For: Nov 24 | SEC filing · Form 6-K | SEC EDGAR | — | +4.16% | |
| Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors | Press release | Business Wire | -1.50% | -3.20% | |
| BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 | Press release | PR Newswire | +0.00% | -4.46% | |
| BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types | Press release | PR Newswire | -1.16% | +3.04% | |
| Form 6-K BioLineRx Ltd. For: Nov 17 | SEC filing · Form 6-K | SEC EDGAR | -1.16% | +3.04% | |
| BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers | Press release | PR Newswire | -0.25% | -6.23% | |
| Form 6-K BioLineRx Ltd. For: Sep 29 | SEC filing · Form 6-K | SEC EDGAR | -0.25% | -6.23% | |
| BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | -3.08% | -2.08% | |
| Form 6-K BioLineRx Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -3.08% | -2.08% | |
| BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 | Press release | PR Newswire | +0.00% | -6.41% | |
| Form 6-K BioLineRx Ltd. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -3.50% | -0.88% | |
| BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | Press release | PR Newswire | -6.02% | -9.48% | |
| Form 6-K BioLineRx Ltd. For: May 30 | SEC filing · Form 6-K | SEC EDGAR | -6.02% | -9.48% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BLRX section they belong to.
Where else BLRX is measured.
BLRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS) | 150 | -0.01% | 48% |
| Sol-Gel Technologies Ltd. - Ordinary Shares (SLGL) | 149 | 0.00% | 42% |
| INMED PHARMACEUTICALS (IMLFF) | 148 | 0.00% | 48% |
| Akari Therapeutics Plc - American Depositary Shares (AKTX) | 146 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioLineRx Ltd. - American Depositary Shares's median reaction calculated?
Every labeled BLRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 148 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of BLRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BLRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.